Element Biosciences stock $6.77 USD
Private-market facts for current and former Element Biosciences employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
Develops next-generation DNA sequencing platforms that offer high accuracy and affordability for genomics research.
Selling Element Biosciences shares
Why shareholders consider selling
Shareholders in Element Biosciences may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Element Biosciences does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Element Biosciences stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Element Biosciences shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Element Biosciences shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round, its reported $1B valuation and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Element Biosciences shareholders
Exploring equity in Element Biosciences often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Element Biosciences most recently raised a Series D round . The company was valued at $1B. Total funding raised to date is approximately $640M.
Lead investors in this round include Foresite Capital and Venrock.
Founders & company background
Element Biosciences was founded in 2017 by Molly He and is headquartered in San Diego, CA.
Investors
Industry
Similar private companies
Latest Element Biosciences news
Frequently asked questions
- Is Element Biosciences still a private company?
- Yes, Element Biosciences is currently a private company.
- What is Element Biosciences's latest funding round?
- Element Biosciences's most recent known round is Series D.
- What is Element Biosciences's valuation?
- Element Biosciences's latest reported valuation is $1B.
- Who are the investors in Element Biosciences?
- Notable investors include Foresite Capital, Venrock.
- Can I sell my Element Biosciences stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Element Biosciences stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Element Biosciences data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.